






Endoscopic management of rectal neuroendocrine tumours. 
How to avoid a mistake and what to do when one is made?
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Abstract 
Rectal neuroendocrine tumours are subepithelial lesions that are potentially malignant. Although the biology of these lesions has become 
increasingly understood and their management has been established, the endoscopic management of these tumours remains controversial. 
Recent studies demonstrated that compliance with guidelines is poor, and the majority of rectal neuroendocrine tumours are removed 
by an improper method, making management more complex and putting patients at risk of metastatic spread. Thus, there is a need to 
educate physicians who care for patients with these disorders. Our review has some tips and pointers for preventing mistakes in primary 
treatment and salvage therapy after polypectomy. (Endokrynol Pol 2020; 71 (4): 343–349)
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Introduction 
Rectal neuroendocrine neoplasms (rNENs) are sub-
epithelial lesions that are diagnosed with increasing 
frequency. They are typically small tumours with low 
malignant potential, but risk of metastasis [1], which 
depends inter alia on the tumour mitotic index, vessel 
infiltration, and size [1]. The endoscopic management of 
rNENs has been established, but controversies remain 
[1–5]. Taking into account their subepithelial origin and 
malignant potential, they should be removed either 
by endoscopic mucosal resection (EMR), endoscopic 
submucosal dissection (ESD), transanal endoscopic 
microsurgery (TEM), or surgery [5]. The removal of 
these lesions with a snare or biopsy forceps results in 
an unacceptably high rate of incomplete resections [6, 
7]. The natural history of rNENs shows that using an im-
proper method to remove the tumour puts patients at 
risk of metastases development, resulting in repeated 
follow-up radiologic, endoscopic examinations and the 
need for salvage therapy [8, 9].
Recent studies have shown that the majority of le-
sions are removed by an improper method, even when 
typical endoscopic features are present, and diagnoses 
are made retrospectively based on histopathological 
assessment [9, 10]. Thus, there is still a need to educate 
physicians caring for patients with rNENs, so that ac-
curate diagnoses are made before the “simple” polypec-
tomy (mistake) is done, and to broaden the knowledge 
of the management after ineffective treatment [11]. 
Herein, we review the key points of endoscopic man-
agement, from diagnosis to treatment. 
Clinical and endoscopic characteristics 
of rectal neuroendocrine tumours: 
diagnosis, management, and avoiding 
mistakes 
Rectal NENs constitute about 1% of rectal neoplastic 
lesions, and they are often accidental findings in colo-
noscopy [5]. Symptoms including changes in bowel 
habits, rectal bleeding, and abdominal pain, which are 
present in 50% of individuals; however, they can be 
attributed more to other underlying diseases (e.g. haem-
orrhoids, irritable bowel disease) than to the presence of 
the tumour itself [5]. Moreover, hormonal activity and 
symptoms of carcinoid syndrome, in contrast to small 
intestinal neuroendocrine tumours (NETs), are rare [1].
Rectal NETs are usually small (< 10 mm in diameter) 
single lesions located 5–10 cm from the dental line [2]. 
Typically, they manifest as regular lesions with yellow 
or white reflexion and smooth intact covering mucosa 
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the best of our knowledge, only a few studies (mainly 
related to gastric lesions) and case reports have assessed 
NETs with NBI [15, 16]. In the study by Lahner et al. all 
gastric type I NETs showed an abnormal surface pat-
tern (tubulovillous or irregular), but with no specific 
features that distinguished them from other lesions 
[15]. In the case report by Lin et al., round pits larger 
than those seen in hyperplastic polyps surrounded by 
honeycomb brown microvessels were typical features 
of rNEN [16]. Taking into account the fact that the basis 
for endoscopic diagnosis is shifting from histopathology 
to advanced methods of imaging, the use of NBI and 
other methods of advanced imaging may be an interest-
ing area of research, and hopefully will be a solution 
for characterising small rectal neuroendocrine polyps 
before they are removed by polypectomy. 
Another area of controversy is the issue of taking 
a biopsy on initial endoscopy. We believe that routine 
biopsies from subepithelial lesions that look typical 
should be avoided, which would not significantly 
change the management strategy (EMR/ESD/TEM/sur-
gery, preceded by endoscopic ultrasound [EUS]). Biopsy 
should only be considered in doubtful cases (atypical 
features) and in tumours that are more than 2 cm in size 
(according to the guidelines, these patients should be 
referred to surgery). The advantage of taking biopsies 
is the significantly high percentage of positive his-
topathological results compared to other subepithelial 
lesions, whereas the disadvantage is that it can lead to 
fibrosis and blur the tumour borders, making further 
endoscopic treatment more complicated from a techni-
cal viewpoint [1, 12]. In the study by Lee et al. biopsy 
of rNENs on initial endoscopy was the only factor that 
was significantly related to the risk of incomplete tu-
mour resection [12]. The authors underlined not only 
the aspect of uncertain tumour borders, which can lead 
to the problems with snaring and targeting the lesion, 
but also of preceding biopsy-related fibrosis, which can 
disturb the ESD or EMR [12].  
(Fig. 1) [1, 2]. Atypical manifestations include lesions 
with central depression/ulceration/scar (Fig. 2), and 
lesions with central hyperaemia or flat seating small 
polyps that are hard to distinguish from hyperplastic 
polyps. The key issue in the initial management of these 
lesions is to suspect rectal NEN based on macroscopic 
features before mistakenly performing routine snare 
polypectomy. A retrospective analysis by Lee et al. [11] 
showed that it was possible to suspect a NET by mac-
roscopic appearance, on endoscopy, in 95.9% of cases 
(94/98 lesions) [12]. These tumours are also described as 
hard and movable, and some authors suggested check-
ing these features with a biopsy forceps as a helpful 
diagnostic tool [12]. 
We postulate that in cases of tumours with typical 
morphology, the reason why rNENs are removed with 
a polypectomy is either routine or poor compliance with 
management guidelines. In a minority of cases, rectal 
NENs present as small lesions, just slightly protruding 
from the mucosa, making them hard to distinguish 
from other polypoid lesions (they resemble hyperplastic 
polyps), and they are routinely removed with biopsy 
forceps or a snare. An outstanding question is whether 
any tools are available that allow physicians to avoid 
a mistake in cases of such small lesions.
Since Kudo’s pit pattern and endoscopic classifica-
tions (e.g. Narrow-band Imaging International Color-
ectal Endoscopic [NICE] classification) for colorectal 
neoplasms were presented with the use of video chro-
moendoscopy — narrow-band imaging (NBI) — we are 
able to predict the histopathology of epithelial lesions 
[13]. In the NICE classification colour for lesions, surface 
(pit pattern) and vessel patterns are assessed to differ-
entiate benign hyperplastic polyps from adenoma, and 
adenoma from cancer. According to the meta-analysis 
by McGill et al., the differential diagnosis of neoplastic 
and non-neoplastic polyps with the use of NBI can be 
made with 91% specificity and 83% sensitivity [14]. To 
Figure 2. Subepithelial lesion with central depression Figure 1. Typical rectal neuroendocrine tumour with yellow 
reflexion
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The endoscopic treatment of lesions more than 
5 mm in size should be preceded by other modali-
ties. An endoscopic ultrasound, according to European 
Neuroendocrine Tumour Society (ENETS) guidelines, 
is indicated for lesions more than 5 mm in size, to 
identify muscular layer invasion and the presence 
of enlarged mesorectal lymph nodes [4, 5]. Studies 
have shown high concordance, reaching more than 
90% (even 100% in the study by Ishii et al.) between 
the assessment of depth of invasion in EUS and post-
operative histopathology [17, 18]. This high accuracy 
allows for treatment planning (i.e. involvement of the 
muscular layer shifts treatment from ESD to TEM or 
surgery when surgery for enlarged lymph nodes is 
indicated). Rectal NENs in EUS typically present as 
hypoechoic, homogenous lesions derived from the 
submucosal layer. Some recent studies show low po-
tential of malignancy and indolent behaviour of small 
rNENs [19–22], suggesting that EUS may not be essen-
tial before endoscopic treatment of rNENs < 10 mm 
in size [19, 21]. This approach that shifts the indica-
tions for EUS (from 5 to 10 mm), taking into account 
earlier observations showing metastatic potential of 
well-differentiated and small rNENs, remains, in our 
opinion, controversial [23].
The recommended methods of treatment are either 
EMR, ESD, TEM, or surgery, depending on tumour 
size and the presence of unfavourable features such 
as advanced histology (G2, G3), lymphangio invasion, 
infiltration of muscular layer, lymph nodes, and distant 
metastases. It should be underlined that the indications 
for endoscopic and surgical treatment proposed by 
different author guidelines differ slightly, as presented 
in Table 1.
Various endoscopic methods have been proposed 
as effective and safe for the treatment of rectal NENs, 
but an important issue is that of which method should 
be offered to patients. When making decisions the 
percentage of R0 resections, complications and the 
presence of muscle layer infiltration, and enlargement 
of lymph nodes in EUS should be taken into account. 
Studies have shown that the R0 resection rate is ob-
tained more commonly with TEM (97.6–100%) than 
with ESD (81.1–100%) and EMR (47.8–80%) (Tab. 2). 
The respectively low R0 resection rate is the reason why 
EMR is generally recommended for small (< 10 mm) 
lesions, and when used, modified methods (cap or liga-
tion band EMR) of resection should be applied [5]. The 
meta-analysis by Zhou et al. comparing ESD and EMR 
for the treatment of rNENs demonstrated higher effi-
cacy of ESD in terms of complete resection rate, with no 
significant differences between ESD and modified EMR 
[24]. There was also no statistically significant difference 
in complication risk; bleeding and perforation occurred 
in similar numbers in both groups of patients (6/209 in 
the ESD group and 6/418 in the EMR group) [24].
The percentage of reported complications of rN-
ENs treatment from ESD (0–9%) is slightly lower than 
that in patients treated with TEM (2.6–13%) (Tab. 1). 
In both methods, the majority of adverse events can 
be treated endoscopically or conservatively with no 
need for open surgical intervention. The advantage 
of TEM (compared to ESD), apart from the higher 
R0 resection rate, is that it can be used as a salvage 
treatment after non-radical therapy (after polypec-
tomy and EMR as well as ESD), also allowing for sam-
pling of perirectal lymph nodes. The disadvantages 
are the aforementioned complications, invasiveness 
of the procedure, and the need for anaesthesia and 
an operating room [25].
Recently, a new method of endoscopic treatment 
for colorectal tumours was presented, with the use of 
an endoscopic full-thickness resection device (FTRD) 
[26, 27]. The study by Meyer et al. on 40 patients with 
rectal NENs showed not only the feasibility (median 
time, 18.5 min) and safety (no major adverse events), 
but also the effectiveness of this method (R0 resec-
tion rate in 95%) [26]. Moreover, in all reported case 
reports of rNEN, FTR showed its effectiveness and 
safety, both for the treatment of primary rectal NEN 
and as a salvage therapy after polypectomy [28–30]. 
Thus, FTR is a promising alternative to the afore-
mentioned methods; however, comparative studies 
in larger groups of patients are needed to confirm its 
safety and efficacy.  
We believe that the treatment method should be 
discussed with the patient, taking into account the 
aforementioned issues (R0 resection rate, complications, 
invasiveness), the EUS results, and the experience of 
the centre. The data comparing methods used for the 
treatment of rectal NENs, including R0 resections and 
complications, are presented in Table 2.
Management after simple polypectomy  
(what to do when a mistake is made)
The ENETS guidelines recommend that all rectal 
NENs be removed with EMR/ESD/TEM or surgery [1, 
4, 5]. This statement is based on the assumption that 
the diagnosis is made on endoscopy, and then the 
patient is referred for treatment, preceded by EUS. 
Unfortunately, this scenario is far from what occurs 
in real life, and in many cases, the neuroendocrine 
origin of the lesion is not suspected on endoscopy and 
the diagnosis is made retrospectively by a pathologist 
[10]. In the study by Fine C et al. on a large group of 
329 patients with small rNEN the suspicion of rNEN 
on endoscopy was made only in 18% of cases; despite 
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this, one third of those that were correctly recognised 
were removed by polypectomy [10]. Polypectomy of 
rectal NENs leads to an unacceptably high incomplete 
resection rate (69.1–83%) and the risk of a presence of 
remnant residual tumour [6, 7, 31, 32]. Endoscopic or 
surgical therapy after non-curative treatment is termed 
salvage therapy. It is based on performing more ad-
vanced treatment than the prior procedure (finding 
and removing the scar or remnant tumour with ESD or 
TEM) or removing the rectum and mesorectal lymph 
nodes with surgery. This adjunct treatment, the same 
as in primary excision, should be preceded by EUS to 
look for the remnant tumour and the presence of lymph 
node metastases. 
The perception of salvage therapy has evolved from 
views that small tumours (< 1 cm) with typical features 
can be removed with snare polypectomy, and in cases of 
incomplete resection, adjunct therapy is recommended 
[1, 17]. This statement has been justified by the presence 
of a high percentage of residual tumours in patients 
who undergo salvage therapy, the risk of metastatic 
spread related to the natural biology of rectal NENs, 
Table 1. Indications for surgical and endoscopic treatment of rectal neuroendocrine neoplasms (rNENs) according to the 
guidelines
Guideline Recommended treatment
ENETS 2012 [4] Surgery:
• > 2 cm
• 1–2 cm with muscularis invasion, nodal positive, G2 T3, T4, G3
TEM: 
• < 1 cm with muscularis invasion, G2, G3
• 1–2 cm without muscularis invasion, nodal negative, G2, T1–T2
• Endoscopy (ESD, EMR < 10 mm):
• < 1 cm without muscularis invasion, G1, G2
• 1–2 cm without muscularis invasion G1
NCCN 2019 [37] Surgery
• T2–T4 > 2 cm
• 1–2 cm with muscularis propria invasion node positive
TEM or endoscopy:
• ≤ 2 cm without muscularis invasion, node negative
• Endoscopic resection (method not specified):
• < 1 cm
NANETS 2010 [38] Surgery 
• > 2 cm
• 1–2 with muscularis invasion, nodal positive
TEM:
• 1–2 cm without muscularis invasion, nodal negative
• consider in T2 tumours, when lymph node metastases are excluded
• Endoscopic resection (method not specified)
• < 1 cm without muscularis invasion
• consider in tumours < 1–2 cm confined to the mucosa/submucosa (T1)
Polish Network of Neuroendocrine 
Tumours 2017 [1]
Surgery
• > 2 cm
• 1–2 cm with risk factors (TEM in individual cases)
Endoscopic resection (ESD):
• < 1 cm
• 1–2 cm without risk factors
ENETS — European Neuroendocrine Tumour Society; NANETS — North American Neuroendocrine Tumour Society; NCCN — National Comprehensive Cancer 
Network; TEM — transanal endoscopic microsurgery; ESD — endoscopic submucosal dissection; EMR — endoscopic mucosal resection 
T1— tumor invades the lamina propria or submucosa; T2 — tumour invades the muscular layer or is ≥ 2 cm in size; T3 — into subserosal tissue; T4 — invades serosa 
and/or adjacent organs — American Joint Committee on Cancer (AJCC) 8th edition [39]
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and long-term observations describing disease recur-
rence after polypectomy [8]. However, the evidence 
supporting this management is not very strong due 
to the lack of large comparative studies comparing the 
outcomes of patients after non-curative endoscopic 
resection who did not undergo adjunct therapy and 
those who underwent salvage treatment.  
Cha et al. followed up a group of 322 patients who 
underwent endoscopic resection of rNENs and found 
that only 31% (44/142) of the patients who did not fulfil 
the criteria of R0 resection underwent salvage therapy 
[11]. Eleven of these patients underwent surgery, and 
lymph node metastases were found in six patients, 
while there were no features of disease progression in 
the remaining patients [11]. The study by Fine et al. in 
patients with rNENs showed a generally favourable 
natural history, and recurrence after endoscopic resec-
tion was only observed in 5% of cases (16/345) in the 
Table 2. Data comparing R0 resection rates and complications after endoscopic mucosal resection (EMR), endoscopic submucosal 
dissection (ESD), and transanal endoscopic microsurgery (TEM)



















Perforation (3.2%), bleeding (3.2%)
Perforation (1.8%), bleeding (6.5%)
Yamaguchi et al. 2010 [42] ESD 20 90% Perforation (5%)
















Bleeding + perforation (6.3%)
Bleeding (3.6%)
Ishii et al. 2010 [18] ESD 22 100% Bleeding (9%)
Kumar et al. 2010 [33] TEM 24 100%
Urinary retention
Entrance to peritoneal cavity
(8.3%)
Kim et al. 2012 [45] TEM 38 97,6% Urinary difficulty (2.6%)























































Meier et al. 2019 [26] FTR 40 95%
Minor bleeding (10%)
Rupture of FTRD snare (2.5%)
(procedure finished with conventional snare)
EMR-C — cap assisted endoscopic mucosal resection; ESMR-L — endoscopic submucosal resection with a ligation device; LCEMR — endoloop ligation  
after cap-endoscopic mucosal resection; FTR — full-thickness resection; FTRD — full-thickness resection device
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median follow-up of 32 months; however, in two cases 
it led to patient death [10]. This study also revealed that 
the neuroendocrine origin of the polyps is suspected 
in a minority of cases on endoscopy, before the polyp-
ectomy is conducted, and even when the diagnosis is 
suspected, many of rNEN are removed with a snare 
polypectomy, justifying the continuous education of 
endoscopists in this field [10]. This conclusion is in ac-
cordance with the results of our study, which showed 
that endoscopists suspected polyps of neuroendocrine 
origin in only 37.5% of cases (9/24 lesions) [9]. 
In studies analysing the pathological results of 
salvage therapies, the presence of remnant tumour in 
resected scars was reported in a significant number 
of cases (4/27 in the study by Kumar et al. [33], 9/21 
in the study by Chen et al. [34], 10/24 in the study 
by Shao et al. [35], and in 7/31 cases in the study by 
Pagano N et al. [36]). In the study by Pagano et al. the 
authors stated that the only independent factor re-
lated to residual disease (present in 22.6% of patients 
treated with ESD as salvage therapy) was the size of 
the polyps, and they showed that ESD was indicated 
in lesions larger than 3 mm (60–90% probability of 
residual disease) [36]. 
In a previous study, the authors performing TEM as 
salvage therapy recommended tattooing the scar with 
an ink before the procedure because they postulated 
that it leads to better visualisation, facilitates FTR, and 
results in a higher percentage of curative resections [33]. 
The disadvantage of scar marking is that it can lead to 
fibrosis and make adjunct endoscopic treatment more 
difficult. The decision on which method (ESD/TEM) 
should be used as optimal for salvage therapy in pa-
tients who do not meet the criteria for surgery should 
be made individually, taking into account the same 
factors as those noted for primary treatment.
Summary and Conclusions
The compliance with guidelines is poor, justifying the 
education of physicians, particularly endoscopists, 
dealing with rNENs, in terms of primary treatment and 
salvage therapy after polypectomy. The polypectomy of 
rectal NETs results in unacceptably high non-curative 
resection rates. The diagnosis of typical submucosal 
lesion should be made on endoscopy, and patients 
should be referred for more advanced treatment 
(EMR/ESD/TEM), preceded by EUS. An endoscopic mu-
cosal resection should be reserved for small (< 10 mm) 
rectal NENs, and when possible, modified methods of 
EMR should be applied. 
ESD and TEM are optimal methods for the treat-
ment of rectal NENs that do not qualify for surgery, 
both of which can be used as primary treatment and 
salvage therapy. Comparative studies and meta-analysis 
are needed to determine which method is optimal for 
treatment in primary and secondary settings.
R0 resection rates, complications, patient preference, 
and experience of the centre are factors that should be 
taken into account when making decisions about therapy. 
Taking into account the feasibility, safety, and ef-
fectiveness FTR seems to be a promising alternative to 
the aforementioned methods in terms of both primary 
and salvage therapy for rNENs.
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